Investors want proof AI will aid drug discovery. Evidence may come in the second half
Nvidia is a fan of Recursion Pharmaceuticals. Data expected from the company will help determine valuations for stocks using AI
Read MoreNvidia is a fan of Recursion Pharmaceuticals. Data expected from the company will help determine valuations for stocks using AI
Read MoreNvidia is investing in Recursion, which uses AI models to identify new therapies and offers those models to its partners,
Read MoreOver the next 12 to 18 months, AI-first drug developers will provide updates on early clinical work that will help
Read More